Related Experiment Video
Updated: Mar 31, 2026
Author Spotlight: Establishment of Pancreatic Cancer-Derived Tumor Organoids and Fibroblasts From Fresh Tissue
Published on: May 26, 2023
What role could organoids play in the personalization of cancer treatment?
Hayley E Francies1, Mathew J Garnett1
1Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridgeshire, CB10 1SA, UK.
Abstract:
Cancer treatments are increasingly being targeted to specific patient populations based on the molecular and genetic features of their tumor, so called precision or personalized cancer medicine. Preclinical cancer models are essential tools for cancer research, but unfortunately our current models often fail to effectively represent patient tumors and can be poorly predictive of clinical responses. In this perspective, we discuss the use of new in vitro 3D cell models called 'organoids' as preclinical cancer models in the context of other commonly used models, namely cancer cell lines and patient-derived xenografts. We consider the relative strengths and limitations of each model, and discuss how organoid culture models could facilitate the personalization of cancer medicine.
Insights
Organoid models offer a promising new approach for preclinical cancer research. These 3D cell cultures better mimic patient tumors, potentially improving the development of personalized cancer medicine.
Area of Science:
- Oncology
- Biomedical Research
- Cancer Therapeutics
Background:
- Precision cancer medicine relies on accurate preclinical models to predict clinical responses.
- Current models like cell lines and xenografts have limitations in representing patient tumor heterogeneity.
- There is a critical need for advanced preclinical models that better recapitulate human tumors.
Discussion:
- Organoids are 3D in vitro cell culture models that mimic the architecture and cellular diversity of patient tumors.
- This perspective compares organoids with traditional cancer cell lines and patient-derived xenografts (PDXs).
- Strengths and limitations of each model are evaluated for their utility in cancer research.
Key Insights:
- Organoid models show potential for higher fidelity in representing patient-specific tumor characteristics.
- They offer a more predictive platform for evaluating drug efficacy and resistance mechanisms.
- Organoid cultures can be derived directly from patient tumors, facilitating personalized treatment strategies.
Outlook:
- Organoid technology could significantly advance the field of personalized cancer medicine.
- Further development and validation of organoid models are crucial for clinical translation.
- Integration of organoids into drug discovery pipelines may accelerate the development of targeted cancer therapies.
